Similarly, SRT1720 inhibits NSCLC via the SIRT1-AMPK pathway, and these effects can be blocked by administration of the AMPK inhibitor Compound C. The inhibitor is also known to inhibit the SIRT1-AMPK signaling pathway. This evidence concerns the gene SIRT1 and non-small cell lung carcinoma.